Getting a clinical trial approved in India means understanding the CDSCO Approval Process. Sponsors must submit their application through the Sugam portal, where it is reviewed by a Subject Expert Committee (SEC) before the Drugs Controller General of India (DCGI) grants permission. The process is governed by the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules, 2019) and follows an affirmative approval model—you must receive formal approval before proceeding, unlike the U.S. IND pathway, where a trial may proceed if no clinical hold is issued within the review period.
For foreign sponsors, the CDSCO Approval Process can appear complex from the outside. However, once you understand each regulatory step—from application submission to DCGI approval—the pathway becomes far more predictable and manageable. Here’s the process, step by step.
The players
CDSCO is India’s national drug regulator. The DCGI, an officer of CDSCO, is the final authority on a clinical trial application. The Subject Expert Committees (SECs) are panels of specialists by therapeutic area that advise CDSCO on whether a trial should proceed. The governing framework is NDCT 2019.
Step 1 — Prepare the dossier to the right standard
The application includes the protocol, the investigator’s brochure, pre-clinical and clinical data, manufacturing and quality information, and the trial agreements. The most common avoidable mistake is assembling this in isolation from the global program — a dossier built by someone who never saw the global protocol invites inconsistencies the SEC will catch.
Step 2 — Submit through Sugam
CDSCO applications are filed online through the Sugam portal, the Agency’s e-governance system. Submission is on defined application forms under NDCT 2019. Clean, complete submissions move; incomplete ones generate queries before substantive review even begins.
Step 3 — Subject Expert Committee review
The SEC for your therapeutic area reviews the application — the science, the data, the protocol, and the rationale. This is the substantive gate. The committee can recommend approval, ask for clarifications, or raise objections. A single unanticipated query can add a cycle.
The sponsors who clear cleanly prepare for the SEC the way they would prepare for an FDA meeting: anticipating the likely questions and addressing them in the dossier, not reacting after the fact.
Step 4 — DCGI permission
If the SEC is satisfied, the DCGI issues permission to conduct the trial. Unlike the U.S. proceed-on-silence default, this is an affirmative authorization — you begin once you have it.
Step 5 — Ethics committee and site approvals
In parallel, each participating site’s ethics committee must approve the study. Registered ethics committees provide the independent review that protects participants. Coordinating CDSCO permission and ethics approvals efficiently is part of a well-run start-up.
Where the time actually goes
Sponsors often assume the timeline is fixed by the Agency. In practice, much of it is determined by the quality of the submission and the readiness for the SEC. A dossier that anticipates the committee’s questions, built with the global filing in view, moves faster than one that triggers rounds of queries. The pathway rewards preparation more than patience.
Frequently asked questions
Q: What is the CDSCO approval process for a clinical trial? A: A sponsor submits a clinical trial application through the Sugam portal under NDCT 2019; a Subject Expert Committee reviews it; and the DCGI issues permission. Site ethics committee approvals run in parallel.
Q: What is the Sugam portal? A: Sugam is CDSCO’s online e-governance system through which clinical trial and drug applications are submitted and tracked.
Q: Does a foreign sponsor need permission before starting a trial in India? A: Yes. India generally requires affirmative DCGI permission before a trial begins — the opposite of the U.S. proceed-on-silence default.
Mapping the India regulatory pathway for your program? Our in-house team manages CDSCO submissions and SEC preparation. → eteraflexconnects.com/services/regulatory-strategy/
